PHOTOCURE ASA (PHO.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:PHO - NO0010000045 - Common Stock
73.65 NOK
+0.45 (+0.61%)
We assign a fundamental rating of 4 out of 10 to PHO. PHO was compared to 54 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for PHO as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, PHO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- PHO had positive earnings in the past year.
- PHO had a positive operating cash flow in the past year.
- In the past 5 years PHO reported 4 times negative net income.
- PHO had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 0.30%, PHO is doing worse than 62.96% of the companies in the same industry.
- With a Return On Equity value of 0.44%, PHO is not doing good in the industry: 64.81% of the companies in the same industry are doing better.
- The Return On Invested Capital of PHO (0.75%) is worse than 70.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.3% | ||
| ROE | 0.44% | ||
| ROIC | 0.75% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- PHO's Profit Margin of 0.39% is on the low side compared to the rest of the industry. PHO is outperformed by 62.96% of its industry peers.
- With a Operating Margin value of 1.11%, PHO is not doing good in the industry: 70.37% of the companies in the same industry are doing better.
- In the last couple of years the Operating Margin of PHO has declined.
- PHO has a better Gross Margin (92.83%) than 96.30% of its industry peers.
- PHO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.11% | ||
| PM (TTM) | 0.39% | ||
| GM | 92.83% |
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
- PHO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, PHO has about the same amount of shares outstanding.
- Compared to 5 years ago, PHO has more shares outstanding
- The debt/assets ratio for PHO has been reduced compared to a year ago.
2.2 Solvency
- PHO has an Altman-Z score of 6.93. This indicates that PHO is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 6.93, PHO belongs to the top of the industry, outperforming 87.04% of the companies in the same industry.
- PHO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.93 |
ROIC/WACC0.09
WACC8.51%
2.3 Liquidity
- PHO has a Current Ratio of 4.25. This indicates that PHO is financially healthy and has no problem in meeting its short term obligations.
- PHO's Current ratio of 4.25 is amongst the best of the industry. PHO outperforms 96.30% of its industry peers.
- PHO has a Quick Ratio of 3.87. This indicates that PHO is financially healthy and has no problem in meeting its short term obligations.
- PHO has a Quick ratio of 3.87. This is amongst the best in the industry. PHO outperforms 96.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.25 | ||
| Quick Ratio | 3.87 |
3. Growth
3.1 Past
- The earnings per share for PHO have decreased strongly by -93.88% in the last year.
- Looking at the last year, PHO shows a small growth in Revenue. The Revenue has grown by 2.15% in the last year.
- Measured over the past years, PHO shows a quite strong growth in Revenue. The Revenue has been growing by 13.29% on average per year.
EPS 1Y (TTM)-93.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%215.38%
Revenue 1Y (TTM)2.15%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%12.26%
3.2 Future
- The Earnings Per Share is expected to grow by 170.05% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 14.98% on average over the next years. This is quite good.
EPS Next Y916.42%
EPS Next 2Y173.5%
EPS Next 3Y170.05%
EPS Next 5YN/A
Revenue Next Year12.38%
Revenue Next 2Y9.18%
Revenue Next 3Y11.27%
Revenue Next 5Y14.98%
3.3 Evolution
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 2455.00 indicates a quite expensive valuation of PHO.
- Based on the Price/Earnings ratio, PHO is valued a bit more expensive than the industry average as 70.37% of the companies are valued more cheaply.
- PHO is valuated expensively when we compare the Price/Earnings ratio to 27.32, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 74.66 indicates a quite expensive valuation of PHO.
- PHO's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. PHO is more expensive than 72.22% of the companies in the same industry.
- PHO is valuated expensively when we compare the Price/Forward Earnings ratio to 24.32, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2455 | ||
| Fwd PE | 74.66 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHO indicates a slightly more expensive valuation: PHO is more expensive than 75.93% of the companies listed in the same industry.
- PHO's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. PHO is more expensive than 61.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 95.29 | ||
| EV/EBITDA | 49.27 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- A more expensive valuation may be justified as PHO's earnings are expected to grow with 170.05% in the coming years.
PEG (NY)2.68
PEG (5Y)N/A
EPS Next 2Y173.5%
EPS Next 3Y170.05%
5. Dividend
5.1 Amount
- No dividends for PHO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
OSL:PHO (1/22/2026, 4:12:38 PM)
73.65
+0.45 (+0.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-29 2025-10-29/bmo
Earnings (Next)02-17 2026-02-17/amc
Inst Owners41.7%
Inst Owner ChangeN/A
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap2.00B
Revenue(TTM)537.59M
Net Income(TTM)2.12M
Analysts82.86
Price Target81.6 (10.79%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)287.09%
Min EPS beat(2)262.02%
Max EPS beat(2)312.16%
EPS beat(4)3
Avg EPS beat(4)96.34%
Min EPS beat(4)-203.96%
Max EPS beat(4)312.16%
EPS beat(8)5
Avg EPS beat(8)80.16%
EPS beat(12)8
Avg EPS beat(12)57.32%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.27%
Min Revenue beat(2)0.47%
Max Revenue beat(2)2.07%
Revenue beat(4)2
Avg Revenue beat(4)-1.22%
Min Revenue beat(4)-5.24%
Max Revenue beat(4)2.07%
Revenue beat(8)4
Avg Revenue beat(8)-2.85%
Revenue beat(12)6
Avg Revenue beat(12)-2.71%
Revenue beat(16)8
Avg Revenue beat(16)-3.97%
PT rev (1m)0%
PT rev (3m)0.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)108.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2455 | ||
| Fwd PE | 74.66 | ||
| P/S | 3.72 | ||
| P/FCF | 95.29 | ||
| P/OCF | 47.73 | ||
| P/B | 4.1 | ||
| P/tB | 7.7 | ||
| EV/EBITDA | 49.27 |
EPS(TTM)0.03
EY0.04%
EPS(NY)0.99
Fwd EY1.34%
FCF(TTM)0.77
FCFY1.05%
OCF(TTM)1.54
OCFY2.1%
SpS19.82
BVpS17.94
TBVpS9.56
PEG (NY)2.68
PEG (5Y)N/A
Graham Number3.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.3% | ||
| ROE | 0.44% | ||
| ROCE | 0.98% | ||
| ROIC | 0.75% | ||
| ROICexc | 1.27% | ||
| ROICexgc | 3.43% | ||
| OM | 1.11% | ||
| PM (TTM) | 0.39% | ||
| GM | 92.83% | ||
| FCFM | 3.9% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-14.8%
ROICexc growth 3YN/A
ROICexc growth 5Y-32.88%
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
F-Score5
Asset Turnover0.77
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 71.25% | ||
| Cap/Sales | 3.89% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 118.67% | ||
| Profit Quality | 989.19% | ||
| Current Ratio | 4.25 | ||
| Quick Ratio | 3.87 | ||
| Altman-Z | 6.93 |
F-Score5
WACC8.51%
ROIC/WACC0.09
Cap/Depr(3y)33%
Cap/Depr(5y)196.94%
Cap/Sales(3y)1.85%
Cap/Sales(5y)14.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%215.38%
EPS Next Y916.42%
EPS Next 2Y173.5%
EPS Next 3Y170.05%
EPS Next 5YN/A
Revenue 1Y (TTM)2.15%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%12.26%
Revenue Next Year12.38%
Revenue Next 2Y9.18%
Revenue Next 3Y11.27%
Revenue Next 5Y14.98%
EBIT growth 1Y-85.73%
EBIT growth 3YN/A
EBIT growth 5Y-13.75%
EBIT Next Year133.71%
EBIT Next 3Y72.02%
EBIT Next 5YN/A
FCF growth 1Y16.48%
FCF growth 3Y47.91%
FCF growth 5Y27.04%
OCF growth 1Y42.41%
OCF growth 3Y47.56%
OCF growth 5Y30.02%
PHOTOCURE ASA / PHO.OL FAQ
What is the fundamental rating for PHO stock?
ChartMill assigns a fundamental rating of 4 / 10 to PHO.OL.
What is the valuation status of PHOTOCURE ASA (PHO.OL) stock?
ChartMill assigns a valuation rating of 1 / 10 to PHOTOCURE ASA (PHO.OL). This can be considered as Overvalued.
Can you provide the profitability details for PHOTOCURE ASA?
PHOTOCURE ASA (PHO.OL) has a profitability rating of 2 / 10.
What is the financial health of PHOTOCURE ASA (PHO.OL) stock?
The financial health rating of PHOTOCURE ASA (PHO.OL) is 9 / 10.
Can you provide the expected EPS growth for PHO stock?
The Earnings per Share (EPS) of PHOTOCURE ASA (PHO.OL) is expected to grow by 916.42% in the next year.